


SUPPLEMENTARY DATA

**Supplementary Figures.** Adapted recommendations for special circumstances. These variations of Fig. 2 in the main text are meant to guide the clinician in choosing agents which may be most appropriate under certain situations: Fig. A when the goal is to avoid hypoglycemia; Fig. B when the goal is to avoid weight gain; and Fig. C when the goal is to minimize costs (in which case the appropriate insulin types are human NPH and human regular). Note that in Figs. A and B, "hidden" agents may obviously still be used when required, but additional care is needed to avoid adverse events. In Fig. A, the risk of hypoglycemia when using the hidden agents will be, in part, dependent on the baseline degree of hyperglycemia, the treatment target, and the adequacy of patient education. In Fig. B, the chances of weight gain when using the hidden agents will be mitigated by more rigorous adherence to dietary recommendations and optimal dosing. Fig. C reflects prevailing costs in the North America and Europe in early 2012; costs of certain drugs may vary considerably from country to country and as generic formulations become available.



**Figure A. Adapted recommendations to avoid hypoglycemia**

SUPPLEMENTARY DATA




Figure B. Adapted recommendations to avoid weight gain

SUPPLEMENTARY DATA

